MVT-602 is an oligopeptide kisspeptin analog that has the potential to be better tolerated than human chorionic gonadotropin as a trigger agent used in controlled ovarian stimulation protocols as part of assisted reproduction for the treatment of female infertility.



Kisspeptin plays a key role in final egg maturation and ovulation by stimulating GnRH secretion, which in turn causes the release of FSH and LH into the systemic circulation.  During the process of egg maturation, FSH stimulates an ovarian follicle--the sac which contains the maturing egg--to grow and the egg within it to develop.  LH triggers ovulation whereby the egg is released from the developing follicle.

Myovant is studying whether MVT-602, an analog of the native kisspeptin peptide in humans, may produce an LH surge in infertile women similar to that occurring naturally in fertile women during a normal menstrual cycle. By mimicking the natural physiologic LH surge during IVF and other assisted reproductive technologies, Myovant is evaluating the likelihood of successful egg maturation and ovulation at the right time without the serious side effect of ovarian hyper-stimulation syndrome, or OHSS. Severe OHSS has been reported to occur in up to 2% of the general population undergoing controlled ovarian stimulation, and in up to 20% of patients who are at high-risk for developing OHSS.

Myovant’s phase 2 trial in up to 85 women is a dose-finding study investigating whether MVT-602 has the potential to trigger ovulation and is initially being evaluated in fertile women undergoing a minimal controlled ovarian stimulation protocol.  Another aim of the study is to determine the optimal time of administration relative to other medications commonly used in controlled ovarian stimulation protocols.